A Phase II Study Using Rituximab Plus Venetoclax in the Front Line

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03078855` - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma	Phase 3
Recruiting	`NCT06006117` - Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma	Phase 3
Active, not recruiting	`NCT04082936` - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04883437` - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	Phase 2
Active, not recruiting	`NCT03697512` - MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas	Phase 2
Terminated	`NCT00772668` - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL	N/A
Terminated	`NCT04189952` - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT05006716` - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies	Phase 1/Phase 2
Terminated	`NCT03919175` - Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma	Phase 2
Recruiting	`NCT06026319` - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma	Phase 1
Active, not recruiting	`NCT03133221` - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2
Terminated	`NCT01500538` - A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)	Phase 2
Not yet recruiting	`NCT05923502` - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Active, not recruiting	`NCT04646395` - Study of Acalabrutinib and Tafasitamab in MZL Patients	Phase 2
Recruiting	`NCT04116437` - Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment	Phase 2
Completed	`NCT02242045` - Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)	Phase 1
Completed	`NCT02927964` - TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04072458` - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies	Phase 1
Completed	`NCT03364231` - Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma	Phase 2

NCT number	NCT04416451
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	May 4, 2021
Completion date	June 2024

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms